Results 131 to 140 of about 27,373 (254)

Time‐dependent wound management protocol prevents periprosthetic joint infection in total knee arthroplasty with persistent drainage

Knee Surgery, Sports Traumatology, Arthroscopy, Volume 34, Issue 5, Page 1740-1749, May 2026.
Abstract Purpose This study aimed to evaluate the success rate of a standardised protocol for managing persistent wound drainage following total knee arthroplasty (TKA). Methods A prospective observational study was conducted at four institutions between January and June 2022 across primary and revision TKAs.
Filippo Leggieri, Francesco Ferriani, Enrico Di Benedetto, Enrick Miani, Enrico Festa, Giovanni Balato, Stefano M. P. Rossi, Francesco Benazzo, Andrea Baldini   +8 more
wiley   +1 more source

The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Background The evidence gap relating to the risk of congenital anomalies (CA) associated with first trimester medication exposure in pregnancy is well recognized. Aims We describe the EUROmediCAT network and databases, and the methodological approach to pregnancy pharmacovigilance.
Helen Dolk, Christine Damase‐Michel, Joan Morris, Amanda Neville, Ester Garne, Sue Jordan, Anke Rissmann, Alessio Coi, Deirdre Folan, Dieuwke Broekstra, Jennifer M. Broughan, Lea Bruneau, Clara Cavero‐Carbonell, Elly den Hond, Miriam Gatt, Mika Gissler, Babak Khoshnood, Anna Latos Bielenska, Hedvig Nordeng, Ljubica Odak, Mary O'Mahony, Isabelle Perthus, J. Luke Richardson, Florence Rouget, Joanna Sichitiu, David Tucker, Natalya Zymak‐Zakutnya, Maria Loane   +27 more
wiley   +1 more source

Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: A scoping review.

PLoS ONE
The safety of antirheumatic drugs in pregnancy and their impact on maternal and neonatal outcomes are understudied. Despite pregnant individuals being excluded from clinical trials, their continued use of medications raises the importance of addressing ...
Shenthuraan Tharmarajah, Araniy Santhireswaran, Yasmeen Ameeriar, Lisa M McCarthy, Dharini Mahendira, Howard Berger, Mina Tadrous, Sara J T Guilcher   +7 more
doaj   +1 more source

Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 791-800, May 2026.
Achieving HbA1c of 6.5–6.9% is associated with a reduced risk of renal complications in patients with diabetes and chronic coronary syndrome. Abstract Aims/Introduction Diabetes mellitus significantly contributes to renal complications, especially in patients with coronary artery disease (CAD).
An‐Yu Cheng, Chin‐Chou Huang, Hsin‐Bang Leu, Wei‐Hsian Yin, Wei‐Kung Tseng, Yen‐Wen Wu, Tsung‐Hsien Lin, Hung‐I Yeh, Kuan‐Cheng Chang, Ji‐Hung Wang, Chau‐Chung Wu, Jaw‐Wen Chen   +11 more
wiley   +1 more source

Antimicrobial effects of folk medicinal plants from the North of Iran against Mycobacterium tuberculosis [PDF]

, 2015
Background: Medicinal plants have been used traditionally in Golestan province (north of Iran), against Mycobacterium tuberculosis or the clinical signs of tuberculosis (TB).
Davoodi, H., Ghaemi, E.A., Ghazisaidi, K., Jahanpour, N., Jahanpour, S., Mazandarani, M., Samet, M.   +6 more
core  

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source

Mandatory Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs Dose Reduction on Risk of Serious Infections in Patients with Rheumatoid Arthritis: A Nationwide Nested Case–Control Study

Biomedicines
Background: We aimed to investigate the risk for a serious infection in rheumatoid arthritis (RA) patients after tapering the dose of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Der-Yuan Chen, Ching-Heng Lin, Hsin-Hua Chen, Yi-Ming Chen, Kuo-Tung Tang   +4 more
doaj   +1 more source

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide

Revista Brasileira de Reumatologia
OBJETIVO: Elaborar recomendações para o tratamento da artrite reumatoide no Brasil. MÉTODO: Revisão da literatura com seleção de artigos baseados em evidência e opinião de especialistas da Comissão de Artrite Reumatoide da Sociedade Brasileira de ...
Licia Maria Henrique da Mota, Boris Afonso Cruz, Claiton Viegas Brenol, Ivanio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Victor Carioca de Freitas, Nilzio Antonio da Silva, Paulo Louzada-Júnior, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima, Geraldo da Rocha Castelar Pinheiro   +11 more
doaj  

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. [PDF]

Front Endocrinol (Lausanne), 2017
Bliddal S, Borresen SW, Feldt-Rasmussen U.   +2 more
europepmc   +1 more source

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS

Научно-практическая ревматология, 2016
Despite major advances in the management of rheumatoid arthritis (RA), whicare associated with the development of new methods for its early diagnosis, the clinical introduction of a wide range of innovative medications and particularly the improvement of
E. L. Nasonov
doaj